Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DLQ01 in Androgenetic Alopecia
NCT05636904Phase 2Completed
- Sponsor
- Dermaliq Therapeutics, Inc.
- Start
- Dec 2022
- Primary completion
- Mar 2024
- Modality
- Transdermal Patches, Hydrogel Systems, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, triple-blind trial of DLQ01 in androgenetic alopecia (AGA) (4 arms), sponsored by Dermaliq Therapeutics, Inc. Primary endpoints: Target Area Hair Count at 28 weeks, Cumulative hair thickness density at 28 weeks and 1 more. Started Dec 2022; status: completed.
02
Drugs
DLQ01
03
Conditions
androgenetic alopecia (AGA)
Beyond the preview
Go deeper on NCT05636904.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05636904.